From the Guidelines
Trimbow is a combination inhaler medication that contains three active components: formoterol fumarate, glycopyrronium bromide, and beclometasone dipropionate. Formoterol is a long-acting beta-2 agonist (LABA) that relaxes the smooth muscles in the airways, providing bronchodilation for up to 12 hours 1. Glycopyrronium is a long-acting muscarinic antagonist (LAMA) that blocks acetylcholine receptors in the lungs, preventing airway constriction and reducing mucus secretion 1. Beclometasone is an inhaled corticosteroid (ICS) that reduces inflammation in the airways by suppressing the activity of inflammatory cells and mediators. This triple combination therapy is typically prescribed for maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD) or asthma in adults who are not adequately controlled with a combination of an ICS and a LABA. The medication is delivered via a pressurized metered-dose inhaler, and the standard dosage is typically two inhalations twice daily. Some key points to consider when prescribing Trimbow include:
- The importance of proper inhaler technique to ensure effective delivery of the medication
- The potential for side effects, such as oral thrush, and the need for patients to rinse their mouth after use
- The need for regular monitoring of lung function and symptoms to adjust the treatment plan as needed
- The potential benefits of Trimbow in reducing exacerbations and improving quality of life for patients with COPD or asthma, as demonstrated in studies such as the one published in Chest in 2015 1. Overall, Trimbow is a valuable treatment option for patients with moderate to severe COPD or asthma who are not adequately controlled with other therapies, and its use should be considered in the context of individual patient needs and medical history.
From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
Components of Trimbow
- Trimbow is a single-inhaler triple therapy that combines three pharmacological agents:
- An inhaled corticosteroid (ICS): beclomethasone dipropionate
- A long-acting β2-agonist (LABA): formoterol fumarate
- A long-acting muscarinic antagonist (LAMA): glycopyrronium bromide 2
- The combination of these three components is designed to improve respiratory function, quality of life, symptoms, and reduce the rate of moderate to severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) 2, 3
Pharmacological Properties
- The triple combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide has been shown to have a good efficacy and safety profile in patients with COPD 4, 3
- The extrafine formulation of the triple combination allows for better lung deposition and improved efficacy 5, 6
Clinical Efficacy
- Clinical trials have demonstrated that Trimbow improves lung function, reduces symptoms, and decreases the rate of exacerbations in patients with COPD 2, 5, 6
- The triple combination has also been shown to improve health-related quality of life, sleep quality, and adherence to treatment in patients with COPD 6